

Barceloneta, Puerto Rico — Governor Jenniffer González-Colón, alongside Department of Economic Development and Commerce (DDEC) Secretary Carlos J. Ríos Pierluisi, today announced a $217 million investment by global biopharmaceutical company AbbVie to modernize and expand its manufacturing operations in Barceloneta.
The expansion project includes the creation of 100 new jobs and the retention of the company’s 1,214 existing direct jobs in Puerto Rico. The reinvestment program, which is expected to continue through 2030, will focus on modernizing critical infrastructure, increasing production capacity, and introducing new products and technologies. The modernization will incorporate advanced manufacturing technologies, including artificial intelligence (AI), to support the production of AbbVie’s current and next-generation medicines in immunology and neuroscience.
“AbbVie’s $217 million investment sends a strong message about Puerto Rico and our ability to compete for high-value manufacturing operations. This global biopharmaceutical company is not only maintaining more than 1,200 jobs on the Island but also investing in additional production capacity and creating 100 new opportunities for our workforce. Our goal is to ensure that companies already operating in Puerto Rico have the conditions they need to reinvest, expand, and increase production here,” said Governor Jenniffer González-Colón.
DDEC Secretary Carlos J. Ríos Pierluisi emphasized that AbbVie’s decision to strengthen and expand its Barceloneta operations reflects Puerto Rico’s competitiveness and the capabilities of its workforce.
“AbbVie’s decision to continue strengthening and expanding its operations in Barceloneta demonstrates Puerto Rico’s competitiveness and the ability of our talented workforce to support world-class biopharmaceutical manufacturing operations. At DDEC, we have worked to establish the conditions that allow companies like AbbVie to grow, innovate, and expand their capabilities from Puerto Rico. This expansion demonstrates the results of those efforts. We remain committed to facilitating investments that strengthen our industrial base, create new economic development opportunities, and generate quality jobs for our people,” said Ríos Pierluisi.
AbbVie’s operations in Puerto Rico include the manufacturing of biologics, including monoclonal antibodies, as well as small molecules, solid oral dosage pharmaceuticals, and active pharmaceutical ingredients for multiple international markets.
According to AbbVie Executive Vice President and Chief Operating Officer Azita Saleki, Ph.D., the planned $217 million investment will be allocated as follows: $121 million for machinery, equipment, and technology, and $96 million for infrastructure and building improvements.
DDEC plans to provide a total of $45.9 million in incentives through its Incentive Fund. Of that amount, $36.3 million would be allocated to machinery, equipment, and technology, while $9.6 million would support infrastructure improvements, Ríos Pierluisi reported.
The expansion is expected to further strengthen economic activity in the Barceloneta region by creating specialized positions in fields such as engineering, automation, validation, quality assurance, and advanced manufacturing.
According to the information provided, the expansion will generate approximately 100 new jobs, increasing AbbVie’s workforce in Puerto Rico to 1,314 employees, with an estimated annual payroll of approximately $118.2 million associated with its operations on the Island.
“Our medicines are essential to the patients who depend on them, and our colleagues in Puerto Rico have long played a critical role in delivering AbbVie treatments to patients. This investment reflects our continued commitment to Puerto Rico and to strengthening our U.S. manufacturing network through the advanced technologies, capabilities, and skilled workforce needed to ensure a consistent and reliable supply of medicines,” said Azita Saleki, Ph.D., AbbVie’s Executive Vice President and Chief Operating Officer.
AbbVie is a global biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative medicines and therapies. The company operates in all 50 states and Puerto Rico and employs approximately 29,000 people across the United States, including more than 6,000 at its U.S. manufacturing facilities and over 1,200 in Puerto Rico.
The project is part of AbbVie’s commitment to invest $100 billion in research and development (R&D) and capital investments, including manufacturing, in the United States over the next decade.
###